Expression and cell-specific localization of cholecystokinin receptors in rat lung

Bin Cong, Shu-Jin Li, Yi-Ling Ling, Yu-Xia Yao, Zhen-Yong Gu, Jun-Xia Wang, Hong-Yu You

INTRODUCTION

Cholecystokinin (CCK) is a gut-brain peptide that exerts a variety of physiological actions in the gastrointestinal tract and central nervous system (CNS) through cell surface CCK receptors. CCK receptors have been pharmacologically classified into two subtypes CCK-A receptor (CCK-AR) and CCK-B receptor (CCK-BR) according to their affinity for the COOH-terminal pentapeptide amide sequence but differ in sulfation at the sixth (gastrin) and seventh (CCK) tyrosyl residues. CCK-AR is highly selective to sulfated analogues of CCK/gastrin peptides and the antagonist L-365 260[3,4]. CCK binds to CCK-AR present on a variety of gastrointestinal target tissues including pancreatic acini, islets, gastric mucosa and gallbladder to induce pancreatic enzyme secretion, insulin secretion, release of pepsinogen and gallbladder contraction[5]. CCK-BR in the CNS regulates feeding, anxiety and memory, etc[6,7]. CCK-AR and CCK-BR are also expressed in the neoplastic cells such as pancreatic cancer cells[8,9], gastric cancer cells[10], colonic cancer cells[11] and small cell lung cancer cells[12,13] where they may stimulate cell growth. Our previous data demonstrated that CCK-8, as an intestinal neuropeptide, not only protected gastric mucosa against alcohol-induced injury[14,15], but also was a potent protective agent against acute lung injury by LPS[16,17]. It obviously reduced the pulmonary artery hypertention (PAH) and lessened the inflammatory lesion in lung tissues of endotoxin shock (ES) rats[18,19]. Moreover, CCK-8 could inhibit the reduction of endothelial-dependent relaxation of isolated pulmonary artery to acetylcholine (Ach) induced by LPS[20]. Stretton and Barnes reported that CCK-8 produced a concentration-dependent contractile response in guinea-pig trachea and this effect was antagonized by the CCK receptor antagonists dibutyl cyclic guanosine monophosphate and L-364 718[21]. These data indicated that there might be CCK receptors in the lung tissues to mediate the action of CCK-8. However, whether CCK receptors are present in lung tissues and their precise cellular localization remains unclear. In the present study, we detected the cellular localization of CCK receptors in the rats’ lung using highly sensitive method of in situ RT-PCR.

MATERIALS AND METHODS

Animal model and tissue preparation

Healthy Sprague-Dawley rats (weighing 180-220 g BW) were anaesthetized with urethane (1 g/kg). Lung tissues were dissected from the rats. The inferior lobe of right lung was fixed in 4 % paraformaldehyde for 1 h and embedded in paraffin for in situ hybridization and in situ RT-PCR.

Primers and probe

The primers and probe of CCK receptor were designed according to Mostein’s report[22]. The sequences of CCK-AR primers were 5’ -CTC GCT CGC CCA GAA CTC TAC CAA GGA ATC AAA TTT GAT GC-3’ (sense) and 5’ -CTG GTT CCG CCC ATG GAG CAG AGG TGC TCA TGT GGC TGT AG-3’ (antisense). The sequences of CCK-BR primers were

RESULTS

METHODS: CCK-AR and CCK-BR mRNA expression and cellular distribution in the rat lung were detected by highly sensitive method of in situ reverse transcription-polymerase chain reaction (RT-PCR) and conventional in situ hybridization. CCK-AR and CCK-BR gene were present in lung tissues and their precise cellular localization remains unclear. In the present study, we detected the cellular localization of CCK receptors in the rats’ lung using highly sensitive method of in situ RT-PCR.

CONCLUSION: CCK-AR and CCK-BR gene were present in pulmonary vascular endothelial cells, macrophages, bronchial epithelial cells and alveolar epithelial cells, which play an important role in mediating the regulatory actions of CCK-8 on these cells.

CONCLUSION: CCK-AR and CCK-BR gene were present in pulmonary vascular endothelial cells, macrophages, bronchial epithelial cells and alveolar epithelial cells, which play an important role in mediating the regulatory actions of CCK-8 on these cells.

Abstract

AIM: To elucidate whether CCK receptors exist in lung tissues and their precise cellular localization in the lung.

METHODS: CCK-AR and CCK-BR mRNA expression and cellular distribution in the rat lung were detected by highly sensitive method of in situ reverse transcription-polymerase chain reaction (RT-PCR) and conventional in situ hybridization.

RESULTS: CCK-AR and CCK-BR gene positive signals were observed in bronchial epithelial cells, alveolar epithelial cells, pulmonary macrophages and vascular endothelial cells of the rats’ lung by in situ RT-PCR. The hybridization signals of CCK-AR were relatively faint. By in situ hybridization, however, only the signals of CCK-BR but not CCK-AR were detected in the lung, and the positive staining was only found in vascular endothelial cells and macrophages.

CONCLUSION: CCK-AR and CCK-BR gene were present in pulmonary vascular endothelial cells, macrophages, bronchial epithelial cells and alveolar epithelial cells, which play an important role in mediating the regulatory actions of CCK-8 on these cells.

REFERENCES:

[1] Cong B, Li SJ, Ling YL, Yao YX, Gu ZY, Wang JX, You HY. Expression and cell-specific localization of cholecystokinin receptors in rat lung. World J Gastroenterol 2003; 9(6): 1273-1277

Correspondence to: Professor Yi-Ling Ling, Department of Pathophysiology, Hebei Medical University, Shijiazhuang 050017, Hebei Province, China. lingyiling@163.net

Received: 2003-01-04   Accepted: 2003-02-11
5’-CTC GCT CGC CCA GAA CTC TAC CTA GGA CTC CAC TTT GA-3’ (sense) and 5’-CTG GTT CGG CCC ACG CAT CAC TAT CCT CAT A-3’ and 5’-AGC TAC GCT GGT TAT AGC CAG CA-3’. The sequences of CCK-AR and CCK-BR probes were respectively 5’-CGG GGG CCG GGG ACT TCT GCA AGT AAC AGC CAT CAC TAT CCT CAT A-3’ and 5’-AGC TAC GCT GGT TAT AGC CAG CA-3’. The oligonucleotide probes were labeled with alkaline phosphatase (Boehringer Mannheim). All the primers and probes were synthesized by Sangon Corporation (Shanghai).

In situ RT-PCR
The sections (5 µm) were baked and deparaffinized to water, and then treated with 0.2 mol/L HCl and EDTA. The slides were pretreated with 0.1 % protease K at 37 °C for 12 min to prevent background staining and inactivate endogenous enzyme. Then the tissues were treated overnight in a Rnase-free DNAase solution (Boehringer Mannheim) at 37 °C. The in situ reverse transcription step was performed in 30 µl solution containing 2 µmol/L CCK-AR or CCK-BR primers and 1 U/µl AMV-RT at 42 °C for 1.5 h. Then the slides were overlain with 50 µl in situ PCR reaction mixture containing 1×PCR buffer, 4.5 mmol/L MgCl₂, 0.2 µmol/L dNTPs, 1 µmol/L each of primers, and 10 U Taq polymerase (Perkin Elmer). The PCR was performed at conditions of initial denaturation at 94 °C for 2 min, followed by 30 cycles of denaturation at 94 °C for 1.5 min, annealing at 55 °C for 1 min, and extension at 72 °C for 1 min. PCR-amplified products were detected with alkaline phosphatase (AP)-labeled CCK-AR and CCK-BR oligonucleotide probes (2 pmol/ml) at 37 °C for 24 h. The slides were then developed in NBT/BCIP solutions at room temperature for 48 h. To stop the color reaction, the slides were washed in distilled water and mounted with glycergel.

Controls
The brain sections were used as positive control. A series of negative controls were performed to guarantee the specificity of the method of in situ RT-PCR. Samples pretreated with RNase were used as negative control. Other five negative controls were samples treated without AMV-RT, or Taq polymerase, or primers, or probes specified or unspecified.

In situ hybridization
The procedure was carried out the same way as in situ RT-PCR, but without the RT-PCR steps.

RESULTS
The positive and negative controls of in situ RT-PCR
The rat brain sections expressed both CCK-AR and CCK-BR. The hybridization signal was present in the neuron. There was no positive signal in RNase-pretreated samples. Omission of AMV-RT, or Taq polymerase, or primers, or probes prevented specific staining (Figure 1, Table 1).

Table 1 Negative controls for in situ RT-PCR

| Reagent         | a | b | c | d | e | f |
|-----------------|---|---|---|---|---|---|
| AMV-RT          | ✓ | ✓ | ✓ | ✓ | × | ✓ |
| Taq polymerase  | ✓ | ✓ | ✓ | × | ✓ | ✓ |
| Primers         | ✓ | ✓ | ✓ | × | ✓ | ✓ |
| Probes          | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| RNase           | ✓ | × | × | × | × | × |
| Probes (Unspecified) | × | √ | × | × | × | × |
| Signal          | - | - | ± | - | - | - |

In situ expression of CCK-BR gene in rat lungs
By in situ RT-PCR, CCK-BR mRNA stainings (dark blue color) were found in bronchial mucosal epithelial cells, endothelial cells, alveolar epithelial cells and macrophages (Figure 2). In situ hybridization, however, CCK-BR mRNA staining was only seen in endothelial cells and macrophages (Figure 3).

In situ expression of CCK-AR gene in rat lungs
By in situ RT-PCR, the hybridization signals of CCK-AR mRNA were also found in bronchial mucosal epithelial cells, endothelial cells, alveolar epithelial cells and macrophages, and the hybridization signals of CCK-AR were weaker than those of CCK-BR (Figure 4). In situ hybridization, however, no expression of CCK-AR mRNA was detected (Figure 5).

Figure 1 Appearance of positive and negative control tissue section for detecting in situ expression of CCK-AR and CCK-BR gene by in situ RT-PCR. (A) In situ expression of CCK-BR gene in the brain of SD rats (×400). (B) In situ expression of CCK-AR gene in the brain of SD rats (×400). (C) Negative control section from the lung tissue of SD rats (×200).
Figure 2 Localization of CCK-BR gene in the lung tissues of SD rats by in situ RT-PCR (×400). (A) Expression of CCK-BR gene in bronchial mucosal cells. (B) Expression of CCK-BR gene in vascular endothelial cells. (C) Expression of CCK-BR gene in macrophages and alveolar epithelial cells.

Figure 3 Localization of CCK-BR mRNA in rat lung tissues by in situ hybridization. (A) Expression of CCK-BR gene in vascular endothelial cells (×100). (B) Expression of CCK-BR gene in vascular endothelial cells and macrophages (×400).

Figure 4 In situ expression of CCK-AR gene in the lung tissues of SD rats, detected by in situ RT-PCR (×400). (A) Expression of CCK-AR gene in vascular endothelial cells. (B) Expression of CCK-AR gene in bronchial mucosal cells and macrophages. (C) Expression of CCK-AR gene in alveolar epithelial cells.

Figure 5 No positive signal of CCK-AR gene was detected in lung tissues by in situ hybridization (×200).
DISCUSSION

In situ RT-PCR is a novel molecular biological technique that combines the high sensitivity of RT-PCR for generating a cDNA from small amounts of mRNA with cellular localization of in situ hybridization. The sensitivity of in situ hybridization is 10-20 copies per cell when detecting the single-copy and low-copy (less than 10 copies) target DNA or RNA in tissues, while using in situ RT-PCR could significantly enhance the sensitivity for detecting the target DNA or RNA. In the present study, we detected the in situ expression of CCK receptors by two methods of in situ hybridization and in situ RT-PCR. By in situ hybridization, only little amount of CCK-BR gene staining was found in vascular endothelial cells and macrophages, whereas by in situ RT-PCR, both CCK-AR and CCK-BR mRNA expressions were detected in bronchial mucosal cells and alveolar epithelial cells other than endothelial cells and macrophages. Our results also demonstrated that the sensitivity of in situ RT-PCR was obviously higher than that of in situ hybridization. Large amounts of cDNA were amplified by specially designed target-specific primers and followed by hybridization with highly specific probes. So the specific binding of nucleotide on the basis of base complementation was performed twice, which increased the specificity of in situ RT-PCR. High sensitivity and specificity made in situ RT-PCR a favorable technique to study the in situ expression and cellular distribution of target gene in tissues. To further ensure the specific results, we designed six negative controls: First, omission of AMV-RT prevented the positive staining, indicating that genome DNA was completely digested. Second, omission of Taq polymerase produced negative results, suggesting endogenous polymerase was inactive. Third, omission of primers produced weak positive reaction which was the results of little amounts of cDNA binding with specific probes, and it confirmed the specificity of the primers. Fourth, addition of RNase produced negative results, confirming that mRNA was detected during RT-PCR. Fifth, omission of specific probes and addition of nonspecific probes produced negative reaction, confirming the specificity of the probes. Sixth, addition of unlabeled specific probes prevented the positive staining, indicating that endogenous alkaline phosphatase was inactive.

Using in situ RT-PCR, we found that CCK-AR and CCK-BR were present in the rats’ lungs. It is the first report about the distribution of CCK receptors in lung tissues. The results of in situ RT-PCR demonstrated the cellular localization of CCK receptors in lung tissues: vascular endothelial cells, macrophages, bronchial epithelial cells and alveolar epithelial cells. Our previous study showed that exposure of rabbit pulmonary artery to LPS or TNF-α led to significant reduction of endothelial-dependent relaxation to Ach and enhancement of contractile response to phenylephrine, which could be reversed by CCK-8. This may be the mechanisms of CCK-8 to abolish PAH during endotoxin shock. The present study showed that pulmonary vascular endothelial cells expressed both CCK-AR and CCK-BR gene. So CCK-8 may bind to CCK receptors on pulmonary vascular endothelial cells to mediate its effects on isolated pulmonary artery. Gu et al. reported that CCK-8 protected cultured bovine pulmonary artery endothelial cells (BPAEC) against the detrimental effect of LPS such as lipoperoxide damages and cell apoptosis as well as LPS-induced peroxynitrite formation, which might be in part reversed by proglumide, a nonspecific CCK receptor antagonist. These data suggested that there might be CCK receptors on BPAEC. Therefore, CCK receptors on pulmonary endothelial cells may mediate effects of CCK-8 on pulmonary vascular such as regulating the reactivity of pulmonary vascular to vasoactive agents and protecting the endothelial cells against damages.

Our present study also demonstrated existence of CCK-AR and CCK-BR gene expression in pulmonary macrophages. It is well known that activation of macrophages plays a critical role in inducing the inflammatory response. Macrophages stimulated by LPS or other inflammatory factors produce and release large quantities of various proinflammatory cytokines including TNF-α, IL-1β, IL-6 etc. Overproduction of these cytokines can result in systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction syndrome (MODS), which might lead to death. So controlling the overactivation of macrophages may be an effective measure in preventing the generation and development of SIRS and MODS. In another study, we found that CCK-8 could inhibit LPS-induced TNF-α release and gene expression in rat pulmonary interstitial macrophages (PIMs) in vitro. The study about its upstream signalling mechanisms demonstrated that CCK-8 inhibited LPS-induced NF-kB activity and iKB degradation in PIMs, which was abrogated by proglumide. Furthermore, LPS-induced expression of LPS receptor CD14 on PIMs could be downregulated by CCK-8 in vitro. These data suggested that CCK-8 might bind to CCK receptors on pulmonary macrophages to interfere with the activation of macrophages during inflammation. But the cellular signal transduction mechanisms through which CCK receptors mediated in macrophages were not fully clarified. Other than pulmonary macrophages, several functions of murine peritoneal macrophages were negatively modulated by CCK-8 including the production of superoxide anion, phagocytosis and mobility. Therefore, CCK receptors on macrophages provide the structural basis for CCK-8 to regulate the functions and activation of macrophages, which may be beneficial to the control of inflammatory responses.

In addition, CCK-AR and CCK-BR mRNA expressions were observed on bronchial epithelial cells and alveolar epithelial cells in this study. Stretton and Barnes reported that CCK-8 produced a concentration-dependent contractile response in guinea-pig trachea and this effect was antagonized by the CCK receptor antagonists dibutyryl cyclic guanosine monophosphate and L-364 718. So the CCK receptors present on bronchial epithelial cells may mediate the regulatory effect of CCK-8 on the tonus of bronchus. The functions of CCK receptors on alveolar epithelial cells remain unclear.

In summary, we successfully detected CCK-AR and CCK-BR mRNA expression in rats’ lung tissues and clarified their cellular localization using in situ RT-PCR. To our knowledge, this is the first report about the CCK receptors gene expression in lung tissues. CCK receptors present on pulmonary endothelial cells, macrophages, bronchial epithelial cells and alveolar epithelial cells play an important role in mediating effects of CCK-8 such as protecting endothelial cells against damages, inhibiting the overactivation of macrophage and regulating the pulmonary vascular tonus and bronchial tonus.

REFERENCES

1. Crawley JN, Corwin RL. Biological actions of cholecystokinin. Peptides 1994; 15: 731-755
2. Wank SA. Cholecystokinin receptors. Am J Physiol 1995; 269: G628-G646
3. Noble F, Roques BP. CCK-B receptor: chemistry, molecular biology, biochemistry and pharmacology. Prog in N eurobiol 1999; 58: 349-379
4. Kulaksiz H, Arnold R, Goke B, Maronde E, Meyer M, Fahrenholz F, Forssmann WG, Eiselle R. Expression and cell-specific localization of the cholecystokinin B/gastrin receptor in the human stomach. Cell Tissue Res 2000; 299: 289-296
5. Wank SA. G protein-coupled receptors in gastrointestinal physiology I. CCK receptors: an exemplary family. Am J Physiol 1998; 274: G607-G613
6 Smith JP, Verderame MF, McLoughlin P, Martenis M, Ballard E, Zagon IS. Characterization of the CCK-C (cancer) receptor in human pancreatic cancer. Int J Mol Med 2002; 10: 689-694

7 Clerc P, Leung-Thaug-Long S, Wang TC, Dockray GJ, Bousson M, Delisle MB, Vaysse N, Pradayrol L, Fourmy D, Dufresne M. Expression of CCK2 receptors in the murine pancreas: proliferation, transdifferentiation of acinar cells, and neoplasia. Gastroenterology 2002; 122: 428-437

8 Pagliocca A, Wroblewski LE, Ashcroft FJ, Noble PJ, Dockray GJ, Varro A. Stimulation of the gastrin-cholecystokinin(B) receptor promotes branching morphogenesis in gastric AGS cells. Am J Physiol Gastrointest Liver Physiol 2002; 283: G292-G299

9 Henwood M, Clarke PA, Smith AM, Watson SA. Expression of gastrin in developing gastric adenocarcinoma. Br J Surg 2001; 88: 564-568

10 Fontana MG, Moneghini D, Villanacci V, Donato F, Rindi G. Effect of cholecystokinin-B gastrin receptor blockade on chemically induced colon carcinogenesis in mice: follow-up at 52 weeks. Digestion 2002; 65: 35-40

11 Reubi JC, Schaer JC, Waser B. Cholecystokinin(CCK)-A and CCK-B gastrin receptors in human tumors. Cancer Res 1997; 57: 1377-1386

12 Matsumori Y, Katakami N, Ito M, Taniguchi T, Iwata N, Takaishi T, Chihara K, Matsu T. Cholecystokinin-B/gastrin receptor: a novel molecular and functional receptor for human small cell lung cancer. Cancer Res 1995; 55: 276-279

13 Behr TM, Jenner N, Radetzky S, Behe M, Gratz S, Yucekent S, Raue F, Becker W. Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin. Eur J Nucl Med 1998; 25: 424-430

14 Domand J, Roche S, Michel F, Bali JP, Cabane S, Faverio J, Magous R. Gastrin-CCK-B type receptors on human T lymphoblastoid Jurkat cells. Am J Physiol 1995; 268: G522-G529

15 Olry C, Gagne D, Cottin E, Bernard N, Galleyrand JC, Berge G, Lignon MF, Eldin P, Le Cunff M, Leger J, Clerc P, Fourmy D, Martinez J. CholecystokininB receptor from human Jurkat lymphoblastic T cells is involved in activator protein-1-responsive gene activation. Mol Pharmaco 1997; 52: 292-299

16 Medina S, Rio MD, Cuadra BD, Guayberas N, Fuente MD. Age-related changes in the modulatory action of gastrin-releasing peptide, neuropeptide Y and sulfated cholecystokinin octapeptide in the proliferation of murine lymphocytes. Neuropeptides 1999; 33: 173-179

17 De la Fuente M, Carrasco M, Del Rio M, Hernanz A. Modulation of murine lymphocyte functions by sulfated cholecystokinin octapeptide. Neuropeptides 1998; 32: 225-33

18 Mercer DW, Cross JM, Smith GS, Miller TA. Protective action of gastrin-17 against alcohol-induced gastric injury in the rat: role in mucosal defense. Am J Physiol 1997; 273: G365-G373

19 Mercer DW, Cross JM, Chang L, Lichtenberger LM. Bombesin prevents gastric injury in the rat: role of gastrin. Dig Dis Sci 1998; 43: 826-833

20 Mercer DW, Smith GS, Miller TA. Cyclooxygenase inhibition attenuates cholecystokinin-induced gastroprotection. Dig Dis Sci 1998: 43: 468-475

21 Ling YL, Huang SS, Wang LF, Zhang JL, Wan M, Hoo RL. Cholecystokinin octapeptide reverses experimental endotoxin shock. Zhongguo Xuehu Qikan Wenzhai 2000; 6: 890-892

22 Gu ZY, Ling YL, Meng AH, Cong B, Hung SS. Effects of cholecystokinin-octapeptide on the response of rabbit pulmonary artery induced by LPS in vitro. Zhongguo Bingli Shengzhi Zhai 1999; 15: 484-487

23 Stretton CD, Barnes PJ. Cholecystokinin-octapeptide constricts guinea-pig and human airways. Br J Pharmacol 1999; 97: 675-682

24 Monstein HJ, Nylander AG, Salehi A, Chen D, Lundquist I, Hakanson R. Cholecystokinin-A and cholecystokinin-B gastrin receptor mRNA expression in the gastrointestinal tract and pancreas of the rat and man. Scand J Gastroenterol 1996; 31: 383-390

25 Bartlett JM. Approaches to the analysis of gene expression using mRNA: a technical overview. Mol Biol Biotechnol 2002; 21: 149-160

26 Peters J, Krams M, Wacker HH, Carstens A, Weisner D, Hamann K, Menke M, Harms D, Parwaresch R. Detection of rare RNA sequences by single-enzyme in situ reverse transcription-polymerase chain reaction. Am J Pathol 1997; 150: 469-476

27 Meng AH, Ling YL, Wang DH, Gu ZY, Li SJ, Zhu TN. Role of nitric oxide in cholecystokinin-octapeptide alleviation of tumor necrosis factor-alpha induced changes in rabbit pulmonary arterial reactivity. Shengli Xuebao 2003; 53: 478-482

28 Gu ZY. Peroxynitrite-mediated pulmonary vascular injury induced by endotoxin and the protective role of cholecystokinin. Shengli Keue Jinzhuan 2001; 32: 135-137

29 Tobias PS, Tapping RI, Gegen JA. Endotoxin interactions with lipopolysaccharide-responsive cells. Clin Infect Dis 1999; 28: 476-481

30 Salomao R, Rigato O, Pignatari AC, Freundenberg MA, Galanos C. Bloodstream infections: epidemiology, pathophysiology and therapeutic perspectives. Infection 1999; 27: 1-11

31 Li SJ, Cong B, Yan YL, Yao YX, Ma CL, Ling YL. Cholecystokinin octapeptide inhibits the in vitro expression of CD44 in rat pulmonary interstitial macrophages induced by lipopolysaccharide. Chin Med J [English Issue] 2002; 115: 276-279

32 Cong B, Li SJ, Yao YX, Zhu GJ, Ling YL. Effect of cholecystokinin octapeptide on tumor necrosis factor α transcription and nuclear factor-κB activity induced by lipopolysaccharide in rat pulmonary interstitial macrophages. World J Gastroenterol 2002; 8: 718-723

33 De la Fuente M, Campos M, Del Rio M, Hernanz A. Inhibition of murine peritoneal macrophage functions by sulfated cholecystokinin octapeptide. Regul Pept 1995; 55: 47-56

34 De la Fuente M, Medina S, Del Rio M, Ferrandez MD, Hernanz A. Effect of aging on the modulation of macrophage functions by neuropeptides. Life Sci 2000; 67: 2125-2135

Edited by Wu XN